Other headlinesSonoSite shows vascular products
Takeover talk drives Hologic stock
Wall Street is buzzing with rumors that Hologic is a takeover target. The rumors have helped drive share prices of the women’s health specialist from a year low of under $12 in early summer to nearly $18 this week. Best known in radiology circles for its digital mammography equipment, Hologic expanded into therapeutics and other women’s products two years ago through a merger with Cytec.
SonoSite shows vascular products
The pioneer of handheld ultrasound is extending its reach in point-of-care medicine with technologies that address patient safety and mobile power for its vascular access ultrasound tools. Bothell, WA-based SonoSite showcased the enhancements at its booth Sept. 14 to 18 during the Association for Vascular Access (AVA) meeting in Las Vegas. Headlining the vascular exhibits are the company’s six-pound NanoMaxx, which is pending FDA clearance, a hand-carried unit that combines one-button operation with a fluid resistant touch screen user interface; LumenVu Catheter Guidance System, which is designed to visualize the placement of peripherally inserted central catheters at the point-of-care; and universal stands that charge batteries onboard SonoSite’s M-Turbo, S Series, NanoMaxx and MicroMaxx product, when the hand-carried systems are docked to the stands.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Clears Point-Of-Care Ultrasound Platform and AI Software for Neuraxial Procedures
July 17th 2025The dual FDA clearances for the Accuro 3S point-of-care ultrasound device and the SpineNav-AI machine learning-based software may enhance precision and safety with ultrasound-guided neuraxial procedures.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.